Drug intelligence / Profile preview

Miniderm

Development stage: Phase 4
Lead developer: ACO
Modality: Small Molecules
Administration: Topical

Overview

Miniderm is a white emollient cream containing 20% glycerol, primarily used for treating dry skin and atopic dermatitis. Glycerol, the active substance, acts as a humectant, binding water to normalize dry skin and strengthen the skin barrier. It is applied topically to alleviate symptoms such as dryness, itching, and flaking.

Brand names: Miniderm
Other names: 20% glycerol cream20% glycerin creamglycerin 20% cream

Beyond the preview

Go deeper on Miniderm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Miniderm.

Explore the full profile